2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The role of ABC transporters in ovarian cancer progression and chemoresistance.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Over 80% of ovarian cancer patients develop chemoresistance which results in a lethal course of the disease. A well-established cause of chemoresistance involves the family of ATP-binding cassette transporters, or ABC transporters that transport a wide range of substrates including metabolic products, nutrients, lipids, and drugs across extra- and intra-cellular membranes. Expressions of various ABC transporters, shown to reduce the intracellular accumulation of chemotherapy drugs, are increased following chemotherapy and impact on ovarian cancer survival. Although clinical trials to date using ABC transporter inhibitors have been disappointing, ABC transporter inhibition remains an attractive potential adjuvant to chemotherapy. A greater understanding of their physiological functions and role in ovarian cancer chemoresistance will be important for the development of more effective targeted therapies. This article will review the role of the ABC transporter family in ovarian cancer progression and chemoresistance as well as the clinical attempts used to date to reverse chemoresistance.

          Related collections

          Author and article information

          Journal
          Crit. Rev. Oncol. Hematol.
          Critical reviews in oncology/hematology
          Elsevier BV
          1879-0461
          1040-8428
          Nov 2015
          : 96
          : 2
          Affiliations
          [1 ] Lung Research, Hanson Institute and Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide.
          [2 ] Data Management and Analysis Centre, University of Adelaide, Australia.
          [3 ] Gynaecological Oncology Department, Royal Adelaide Hospital, Australia; School of Paediatrics and Reproductive Health, Robinson Research Institute, University of Adelaide, Australia.
          [4 ] School of Paediatrics and Reproductive Health, Robinson Research Institute, University of Adelaide, Australia. Electronic address: carmela.ricciardelli@adelaide.edu.au.
          Article
          S1040-8428(15)00101-8
          10.1016/j.critrevonc.2015.05.012
          26100653
          5c362f62-14d4-4e0d-8dd2-276932325389
          History

          ABC transporter,Chemoresistance,Clinical trials,Multi-drug resistance,Ovarian cancer,Prognosis

          Comments

          Comment on this article